GET DAILY SIGNALSFractyl Health (GUTS): Can the Stock Reach the $6 Analyst Target with +711% Upside?
Key Takeaways
- The central target of $6 is the arithmetic mean of three verified, current analyst price targets: $8, $8, and $2.
- With the stock trading around $0.74, reaching $6 would require a move of roughly 711% — a very large gain by any measure.
- The analyst target range is exceptionally wide, from $2 to $8, reflecting deep disagreement about the company's risk profile.
- The strongest supports are clinical data from the Revita and Rejuva programs aimed at weight maintenance after GLP-1 drug discontinuation and type 2 diabetes.
- The biggest risks are Nasdaq listing-compliance concerns, heavy cash burn, and uncertainty in clinical and regulatory outcomes.
- Views are sharply split: H.C. Wainwright and Canaccord Genuity remain bullish at $8, while Morgan Stanley has cut its view to a $2 Equal-Weight target.
- For deeper coverage of Fractyl Health's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated analysis pages.
Understanding the Analyst Consensus
The $6 central target comes directly from three attributable analyst calls. H.C. Wainwright's Joseph Pantginis maintains a Buy rating with an $8 price target, and Canaccord Genuity's Whitney Ijem does the same at $8. Morgan Stanley downgraded the name from Overweight to Equal-Weight in January 2026 following Revita trial updates and now carries the most conservative $2 target. Averaging the three produces exactly $6.00. Broader aggregator averages sit in a similar $5–$6 band, with the same $2 low and $8 high, underscoring how divided opinions remain on the binary clinical risk.
In my view, that spread reflects fundamentally different assessments of the company's ability to execute. Bullish analysts highlight positive REMAIN-1 data on durable weight maintenance after GLP-1 discontinuation, while Morgan Stanley's caution centers on trial timelines and ongoing financing needs. The $6 figure is best read as a midpoint across divergent scenarios rather than a single-point forecast.
Where the Stock Stands Today
GUTS trades near $0.74 after declining more than 90% over the past year. Reaching the $6 central target would imply upside of approximately 711%, a move typical of a successful late-stage biotech re-rating. The company posted a GAAP net loss of $25.5 million in the June 2026 quarter, improved from the $27.9 million loss a year earlier, but meaningful revenue remains absent. Any path to the target would likely require positive pivotal data, regulatory traction, and resolution of capital and listing issues.
Pipeline Strengths That Could Drive Growth
Fractyl Health's pipeline forms the core bull case. Revita, a duodenal mucosal resurfacing procedure, is advancing in pivotal studies for post-GLP-1 weight maintenance, targeting patients who discontinue therapies from Novo Nordisk or Eli Lilly and subsequently regain weight. Mid-2026 REMAIN-1 data demonstrated durable weight-loss maintenance, a point the bullish analysts emphasize. The company has also moved Rejuva, its gene therapy candidate, into first-in-human studies for type 2 diabetes, providing a second, longer-term catalyst. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Key Risks on the Horizon
The risks are concrete. The company has faced Nasdaq listing-compliance pressure and executed a reverse stock split to meet the minimum-bid requirement, signaling balance-sheet strain. Recurring operating losses necessitate ongoing capital raises that dilute shareholders. Clinical outcomes remain uncertain; a disappointing pivotal readout, regulatory delay, or funding shortfall could undermine the higher targets. Competition from established GLP-1 products further raises the bar. Morgan Stanley’s $2 target captures these execution and financing concerns.
Technical Picture and Volatility
Given the sharp decline and thin trading volume, technical structure revolves around psychological and round-number levels rather than established patterns. The $1 mark serves as notable resistance on any recovery attempt, while the 52-week range from well below $1 to several dollars illustrates the volatility. For a name that has lost the majority of its value, event-driven catalysts around data releases and financing announcements carry more weight than classic chart levels.
What to Watch Going Forward
Analyst targets generally reflect a 12-month horizon, though for a pre-revenue biotech the effective period often aligns with the next major clinical event. Investors should track pivotal Revita results, Rejuva first-in-human progress, quarterly cash runway commentary, any financing activity, and updates on Nasdaq compliance. The next earnings report, scheduled for November 11, 2026, will matter primarily for cash and guidance details.
Using AI Daily Buy/Sell Signals for Volatile Names
AI Daily Buy/Sell Signals from Tickeron applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on market conditions and technical behavior. For an event-driven name like GUTS, these signals can help surface opportunities and track shifts more efficiently than manual review alone. I find this approach useful as a systematic complement when evaluating clinical-stage biotechs.
Final Assessment
Can Fractyl Health (GUTS) reach $6? The $6 central target, derived from verified calls at $8, $8, and $2, sits roughly 711% above the current price. That magnitude of move only appears plausible under a successful clinical and regulatory scenario. The bull case rests on Revita’s post-GLP-1 opportunity and Rejuva’s gene-therapy potential, while the bear case centers on listing pressure, cash burn, and binary trial risk. With analysts split between $2 and $8, the $6 level is best viewed as a midpoint of divergent outlooks rather than a consensus forecast. Focus on upcoming data, financing moves, and compliance developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GUTS's Stochastic Oscillator remains in oversold zone for 16 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +3.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where GUTS advanced for three days, in 104 of 123 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
GUTS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GUTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GUTS entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GUTS's P/B Ratio (-84.131) is slightly lower than the industry average of (3.037). P/E Ratio (-0.967) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. GUTS's P/S Ratio (10000.000) is very high in comparison to the industry average of (439.237).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. GUTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GUTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement